Graded Eccentric Rehabilitation After Adipose-Derived Stem Cell Injection for Knee Osteoarthritis: A Systematic Review
DOI:
https://doi.org/10.19166/med.v15i3.11629Keywords:
adipose-derived mesenchymal stem cells, graded eccentric rehabilitation, knee osteoarthritis, stromal vascular fraction, systematic reviewAbstract
Background:
Knee osteoarthritis is a leading cause of disability worldwide, and adipose-derived cell therapies have emerged as potential disease-modifying interventions. However, no direct evidence exists for graded eccentric rehabilitation following adipose-derived cell injection. This systematic review synthesized the indirect clinical evidence from adipose-derived mesenchymal stem cell, stromal vascular fraction, and microfragmented adipose tissue injection trials for knee osteoarthritis to characterize post-injection rehabilitation practices, efficacy, and safety.
Methods:
PubMed, EMBASE, and Scopus were searched from inception through 15 May 2026. Eligible studies were human clinical trials of intra-articular adipose-derived cell or stromal vascular fraction injection for knee osteoarthritis reporting pain, function, imaging, or safety outcomes. Study selection was performed independently by all authors, with discrepancies resolved through discussion. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool for randomized trials and the Risk of Bias in Non-Randomized Studies of Interventions tool for observational studies.
Result:
Eighteen studies (811 participants) were included. No study directly examined graded eccentric rehabilitation after adipose-derived cell injection. Post-injection protocols ranged from simple rest to conventional physiotherapy. Most randomized controlled trials demonstrated significant improvements in pain and function scores, with favorable safety profiles. Risk of bias ranged from low-to-some concerns in placebo-controlled trials to serious in uncontrolled cohort studies.
Conclusions:
Adipose-derived cell therapies for knee osteoarthritis demonstrate promising short-to-medium-term clinical benefits with acceptable safety. However, the complete absence of graded eccentric rehabilitation protocols in the existing literature represents a critical evidence gap warranting future investigation.
References
1. Yokota N, Yamakawa M, Shirata T, Kimura T, Kaneshima H. Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee. Regen Ther. 2017;6:108-112.
2. Freitag J, Bates D, Wickham J, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoasrthritis: a randomized controlled trial. Regen Med. 2019;14(3):213-230.
3. Hong Z, Chen J, Zhang S, et al. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019;43(5):1123-1134.
4. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504-511.
5. Lu L, Dai C, Zhang Z, et al. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019;10(1):143.
6. Zhao X, Ruan J, Tang H, et al. Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells. Stem Cell Res Ther. 2019;10(1):353.
7. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial. Am J Sports Med. 2020;48(6):1462-1472.
8. Heidari N, Noorani A, Slevin M, et al. Patient-centered outcomes of microfragmented adipose tissue treatments of knee osteoarthritis: an observational, intention-to-treat study at twelve months. Stem Cells Int. 2020;2020:8881405.
9. Chen CF, Hu CC, Wu CT, et al. Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial. Stem Cell Res Ther. 2021;12(1):562.
10. Tsubosaka M, Matsumoto T, Sobajima S, et al. Comparison of clinical and imaging outcomes of different doses of adipose-derived stromal vascular fraction cell treatment for knee osteoarthritis. Cell Transplant. 2021;30:09636897211067454.
11. Yokota N, Hattori M, Otsuaki T, Suda Y, Haro H. Clinical safety and effectiveness of adipose-derived stromal cell vs stromal vascular fraction injection for treatment of knee osteoarthritis: 2-year results of parallel single-arm trials. Am J Sports Med. 2022;50(9):2544-2557.
12. Kim YS, Suh DS, Yun SJ, et al. Clinical efficacy and safety of the intra-articular injection of autologous adipose-derived mesenchymal stem cells for knee osteoarthritis: a phase III, randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2023;51(9):2432-2442.
13. Sadri B, Hassanzadeh M, Bagherifard A, et al. Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial. Stem Cell Res Ther. 2023;14(1):162.
14. Freitag J, Wickham J, Shah K, Li D, Norsworthy C, Bates D. Safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell preparation in the treatment of knee osteoarthritis: a phase I/IIa randomised controlled trial. Osteoarthr Cartil Open. 2024;6(3):100500.
15. Lu Y, Zhang J, Li M, et al. Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis: a prospective randomized controlled clinical trial. Sci Rep. 2025;15(1):12345.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Faulina Yosia Panjaitan, Himawan Widyatmiko, Farkhana Dwi Ariyani, Aisyah Muthia Rasyida
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
